XML 33 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenues $ 2,400,311 $ 2,550,046 $ 8,919,312 $ 7,501,535
Cost of Sales 998,320 1,269,005 5,010,704 3,995,792
Gross Profit 1,401,991 1,281,041 3,908,608 3,505,743
Operating Expenses:        
Loss on inventory investment 1,285 1,226,426
Wage and salary expense 937,062 1,015,816 3,185,144 2,878,237
Professional fees 95,275 205,457 307,341 757,263
Accounting and legal expense 191,611 98,867 567,690 462,626
Technology expense 298,586 338,637 842,433 678,110
General and administrative 286,488 917,105 1,484,709 2,013,050
Total operating expenses 1,809,022 2,577,167 6,387,317 8,015,712
Operating Loss (407,031) (1,296,126) (2,478,709) (4,509,969)
Nonoperating income (expense)        
Interest income 8,396 8,396
Gain on disposal of asset 4,100
Interest expense (130,107) (5,622) (140,626) (21,574)
Total nonoperating expense (121,711) (5,622) (128,130) (21,574)
Net Loss (528,742) (1,301,748) (2,606,839) (4,531,543)
Net loss attributable to TRxADE Health, Inc. (503,003) (1,301,748) (2,546,913) (4,531,543)
Net loss attributable to non-controlling interests $ (25,739) $ (59,926)
Net loss per common share — basic and diluted $ (0.06) $ (0.16) $ (0.31) $ (0.56)
Weighted average common shares outstanding - basic and diluted 8,249,653 8,163,522 8,203,202 8,126,689